TY - CONF AU - Puerta, JM AU - Jiménez Velasco, A AU - García, MJ AU - Molina, JR AU - Ruiz, C AU - Ferrer, C AU - Durán, MS AU - Simón, I AU - Clavero, E AU - Avellaneda, MC AU - Rosell, A AU - Ballesteros, I AU - Ramírez, S AU - Portero, MA AU - Ramírez, MJ AU - Fernández, M AU - Jiménez, M AU - Fe, R AU - Mulero, N AU - López, P PY - 2016 SN - 0390-6078 UR - http://hdl.handle.net/10668/2445 T2 - Haematologica AB - Even though they were approved last June 2011 to be used on first line, it is not a common procedure to begin treatment of CML-CP with 2GTKI, despite it has been demonstrated its efficacy and safety against imatinibon ENESTnd and Dasision clinical... LA - en PB - Ferrata Storti Foundation KW - Dasatinib KW - Humanos KW - Mesilato de imatinib KW - Leucemia mielogenosa crónica BCR-ABL positiva KW - Pirimidinas KW - Sistema de registros KW - Andalucía KW - Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::Thiazoles::Dasatinib KW - Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans KW - Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amides::Benzamides::Imatinib Mesylate KW - Medical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia, Myelogenous, Chronic, BCR-ABL Positive KW - Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyrimidines KW - Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Registries TI - Efficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC) TY - conference presentation ER -